Background:
Physostigmine is a naturally-occurring compound first isolated from the extract of the West African Calabar bean (PIzysostipnza verzoszcn~) in 1864. In the same year, a crude Calabar bean extract was first used as an antidote for anticholinergic toxicity among three prisoners ingesting belladonna.' Sincc that time. physostigmine has been used to trcat glaucoma, post-operative ileus. and atropine-induced coma.' Physostigminc's popularity as an antidote grew in the late 1960s and 1970s. particularly for the treatment of altered mental status associated with tricyclic antidepressant poisoning." A 1980 report of asystole complicating physostigmine use in two patients with serious tricyclic antidepressant poisoning4 heralded a retreat fi-om indiscriminate use of the antidote. More recently. opinion has shifted again towards favoring the cautious use of physostiglnine as an antidote in selected cases of anticholinergic toxicity.'
Clinical Pharmacology:
Acetylcholine is a neurotransmitter that acts at muscarinic and nicotinic receptors of the cholinergic nervous system. Under notmal conditions, the action of acetylcholine is quickly tcrminated by the enzyme acetylcholinesterase (Ach) found in the synaptic cleft. Drugs and other compounds that are typically classified as "anticholinergic" are actually antimuscarinic, since they block the effect of acetylcholine at rnuscarinic receptors within the central nervous system, in peripheral ganglia, and on effector organs of the autonomic nervous system. namely the exocrine glands (bronchial, sweat. lacrimal); and cardiac and smooth muscles. Such anticholincrgic agents include many antihistamines, antiparkinsonian dnlgs, antipsychotics, antispasmodics. tricyclic antidepressants, belladonna alkaloids and co~npounds found in several other poisonous plants and f i~n g i .~
Physostigmine is a carbamate that reversibly inhibits acetylcholinesterase. Physostiglnine acts as a competitive substrate for Ach, allowing acetylcholine to accumulate in the synaptic clefts and overcome the blockade of muscarinic receptors by the anticholinergic agents. Because physostigmine is a tertiary amine. it is uncharged. lipophilic, and easily crosses the blood-brain barrier.-This action allows physostigmine to reverse toxic CNS effects, whereas other carba~nate dmgs that are charged quaternary a~nines (such as neostigmine and pyridostigmine) will only reverse peripheral signs and symptoms. Physostigmine's ability to reverse central effects led to its trade name of AntiliriurnB, since it can reverse the delirium associated with anticholinergic toxicity.
Indications:
Physostigmine treatment may be indicated for patients with moderate to severe anticholinergic poisoning with evidence of both peripheral and central toxicity.Vhysostigmine is not generally considered a first-line agent, and should probably be reserved for paticnrs with potentially life-threatening complications of anticholinergic toxicity that are unresponsive to standard treatment regimens. Such complications include severe agitation, seinires. persistent hypertension, and heinodyna~nic compromise secondary to tachycardia (i.e. unstable narrow complex dysl-rhythmias).
In addition to a therapeutic role in clear-cut cases of anticholinergic poisoning, physostigmine also has a potential diagnostic role. In patients with altered levels of consciousness, who bv relevant history and examination may be suffe~ing from anticholinergic poisoning, a test dose of physostigmine may help to confinn the diagnosis. If the patient's mental status significantly improves, more invasive and timeconsuming diagnostic tests. such as lumbar puncture and cranial computed tornogaphy, may be avoided;'.' this is particularly true if thc paticnt is then able to identify the substance ingested. One caution must bc noted: physostigrnine is an "analeptic" agent and may cause non-specific arousal whcn used in the presence of many drugs causing depressed mental status. Therefore, minor improvelnents in a patient's level of consciousness do not prove that they wcre poisoned with an anticholinergic agent.
Dosing and Precautions:
The initial dose of physostigmine is 1-2 mg in adults and 0.02 mglkg in children administered slowly IV over at least 5 minutes. Many physicians are even Inore cautious, and utilize 0.5 mg aliquots. titrated slowly to desired effect. Rapid administration is associated with induction of seizures.' Bccause of its short half-life and rapid elimination, the clinical effects of physostigmine are short in duration. Repeat dosing every 20-60 minutes may be needed to correct the recul-rence of life-threatening conditions initially treated with the first dose."' Continuous physostigmine infiisions have been reported but are not rccommended. Although effective in reversing anticholinergic toxicity, treatment with physostignlinc can lead to adverse side-effects and complications. Excessive doses of physostigmine may induce cholinergic toxicity. Prior to administering physostigmine, rcaction to potential complications should be anticipated. Urinary outlet obstl-~lction can be prevented by the placement of a Foley catheter and bedside s~lction should be immediately available if needed to clear excess salivation, bronchial secretions. or emesis. The patient should also be placed on continuous electrocardiographic and pulse oximetry monitoring. Close physician supervision during and immediately following physostigrnine administration is desirable. Atropine should also be rapidly available to counteract excessive cholinergic tone, and is administered IV at a dose equal to half the initial dose of physostigmine if such complications o c c i~r .~ Serious but relatively infrequent complications, such as seizures, symptonlatic bradycardia, and bron-chospasm, hake been assoc~ated w~t h physostlgnnne treatment ' '
Contraindications:
The contraindications to physostigrninc use form one of the most controversial issues regal-ding the d n~g .
Several conditions listed as contraindications are predictable, as enhancing cholinergic tone may exacerbate them, including asthma. chronic obstnlctive pulmonary disease. atherosclerotic heart disease. bradycardia, peripheral vascular disease, genitourinary and gastrointestinal obstruct i o n , ' .~~~ Many sources list tricyclic antidepressant (TCA) overdose and prolongation of the QRS complex on the ECG 2 0.10 scc as absolute contraindications to physostigmine." Use in these circumstances has been associated with severe bradyarrhythrnias and asystole. ' The contraindication against physostigmine use in TCA overdose patients has reached the status of treatment dogma despite the fact that it is based on only a few case reports. We could find only 4 reported cases of asystole associated with physostigmine use if the setting of TCA o v e r d~s e . '~-~" In contrast, numerous case reports and series have documented successful treatment of TCA overdose with physostigmine without scrious cardiac side effects or coniplications, only a few examples of which are referenced here, I .' .' .(,.-Indeed, physostigrnine had been considered the treatment of choice for neurologic arid cni.diac complications of TCA overdose in the early 1970s.' This disparity niost likely stems from several causes: I) reporting bias, where positive outcomes are more likely to be submitted for publication. 2) the cardiotoxicity of TCAs was not as well understood in decades past, and the reversal of altered mental status appeared to be the primary therapeutic goal: 3) TCA overdose can present with a spectnun of disease, where mildly toxic TCA overdose patients may benefit from reversal of CNS anticholinergic effects. while seriously poisonedpatients are more prone to severe bradyarrhythmias and asystole. The associated clcctrocardiograpliic contraindications to physostigmine rely on using the QRS complex as a surrogate marker for TCA toxicity." where a prolonged QRS is presumed to represent a patient at risk for complications with physostigminc. Bums et nl. recently reported 5 patients (from a larger case series) with known amitriptyline overdose who suffered no serious complications from physostigrnine given to reverse anticholinergic effects. But even so, all these patients had ECGs documenting a QRS interval less than 0.10 seconds and were given physostigmine at least 12 hours after the initial inge~tion.~ Thus, it appears that TCA overdose alone is not an absolute contraindication to physostigmine use. It may still be prudent, however, to withhold physostigniinc when there is any evidence of QRS interval prolongation.
Summary -Using Physostigmine in the ED:
Since physostigmine is relatively short-acting, and because luany aspects of anticholinergic toxicity can bc nianaged by standard treatment regimens (e.g. benzodiazepines for agitation or seizures). the ideal role of physostigmine in the ED has not been clearly determined. Physostigmine's prirna~y role is probably as a back-up agent in cases where standard treatment fails for neurologic and cardiac con~plications of anticholinergic toxicity. Furthennore. physostigmine appears to have some benefit over bcnzodiazepines in the ~nanagcment of anticholinergic-induced agitation.' In some cases with features suggestive of anticholinergic toxicity but where the differential diagnosis remains broad, physostigmine may confirm the diagnosis and obviate the need for additional invasive or expcnsive testing. Further review and prospective analysis concerning its use in the setting of TCA overdose or QRS interval prolongation is needed to provide clear-cut contraindications. When used with proper precautions. however, physostig~nine can be a valuable tool in the ED armamentarium.
